title: Automated measurement of unsaturated iron binding capacity is an effective screening strategy for C282Y homozygous haemochromatosis.
abstract: BACKGROUND
  C282Y hereditary haemochromatosis is an appropriate condition for population screening. Transferrin saturation, the best screening test to date, is relatively expensive, labour intensive, and cannot be automated. Unsaturated iron binding capacity is a surrogate marker of transferrin saturation and its measurement can be automated.
  
  
  OBJECTIVE
  To evaluate a screening strategy for C282Y hereditary haemochromatosis in a tertiary hospital environment based on unsaturated iron binding capacity as the initial screening test.
  
  
  METHODS
  Measurement of unsaturated iron binding capacity was adapted to the main laboratory analyser. An unsaturated iron binding capacity of less than 30 micromol/l was identified as an appropriate decision point and 5182 consecutive subjects were screened over 28 consecutive days.
  
  
  RESULTS
  Of those screened, 697 had an unsaturated iron binding capacity less than 30 micromol/l. Of these, transferrin saturation was greater than 40% in 294. A total of 227 were able to be genotyped for the C282Y mutation. Nine subjects homozygous for C282Y were identified. Based on full cost recovery, affected persons were identified at a cost of Aus$2268.77 per case (approximately US$1496).
  
  
  CONCLUSIONS
  Automated measurement of unsaturated iron binding capacity enables a cost effective, large scale population screening programme for C282Y hereditary haemochromatosis to be developed.
authors.affiliation: Department of Chemical Pathology, Princess Alexandra Hospital, Brisbane, Australia.
authors.forename: P E
authors.initials: PE
authors.lastname: Hickman
authors.forename: L F
authors.initials: LF
authors.lastname: Hourigan
authors.forename: L W
authors.initials: LW
authors.lastname: Powell
authors.forename: F
authors.initials: F
authors.lastname: Cordingley
authors.forename: G
authors.initials: G
authors.lastname: Dimeski
authors.forename: B
authors.initials: B
authors.lastname: Ormiston
authors.forename: J
authors.initials: J
authors.lastname: Shaw
authors.forename: W
authors.initials: W
authors.lastname: Ferguson
authors.forename: M
authors.initials: M
authors.lastname: Johnson
authors.forename: J
authors.initials: J
authors.lastname: Ascough
authors.forename: K
authors.initials: K
authors.lastname: McDonell
authors.forename: A
authors.initials: A
authors.lastname: Pink
authors.forename: D H
authors.initials: DH
authors.lastname: Crawford
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003362:Cost-Benefit Analysis; D005069:Evaluation Studies as Topic; D005260:Female; D005819:Genetic Markers; D005820:Genetic Testing / Q000191:economics / Q000379:methods*; D005838:Genotype; D006432:Hemochromatosis / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D014168:Transferrin / Q000378:metabolism*
chemical_list: D005819:Genetic Markers; D014168:Transferrin; D007501:Iron